Neoantigen　vaccine　is　a　promising　breakthrough　in　tumor　immunotherapy.　However,　the　application　of　this　highly　personalized　strategy　in　the　treatment　of　solid　tumors　is　hindered　by　several　obstacles,　including　very　costly　and　time-consuming　preparation　steps,　uncertainty　in　prediction　algorithms　and　tumor　heterogeneity.　Universalization　of　neoantigen　vaccine　is　an　ideal　yet　currently　unattainable　solution　to　such　limitations.　To　overcome　these　limitations,　we　engineered　oncolytic　viruses　co-expressing　neoantigens　and　neoantigen-binding　major　histocompatibility　complex　(MHC)　molecules　to　force　ectopic　delivery　of　peptide-MHC　ligands　to　T　cell　receptors　(TCRs),　enabling　specific　targeting　by　neoantigen　vaccine-primed　host　immunity.　When　integrated　with　neoantigen　vaccination,　the　engineered　viruses　exhibited　potent　cytolytic　activity　in　a　variety　of　tumor　models　irrespective　of　the　neoantigen　expression　profiles,　eliciting　robust　systemic　antitumor　immunity　to　reject　tumor　rechallenge　and　inhibit　abscopal　tumor　growth　with　a　favorable　safety　profile.　Thus,　this　study　provides　a　powerful　approach　to　enhance　the　universality　and　efficacy　of　neoantigen　vaccines,　meeting　the　urgent　need　for　universal　neoantigen　vaccines　in　the　clinic　to　facilitate　the　further　development　of　tumor　immunotherapy.